Oppenheimer Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Oppenheimer Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.9M	Sell	19,608 -234	-1%	-$70.6K	0.06%	324
2026 Q1	$6.57M	Buy	19,842 +4,250	+27%	+$1.45M	0.07%	282
2025 Q4	$6.2M	Buy	15,592 +11,292	+263%	+$5M	0.08%	261
2025 Q3	$1.96M	Buy	4,300 +2,972	+224%	+$1.21M	0.02%	573
2025 Q2	$433K	Buy	+1,328	New	+$367K	0.01%	912
2020 Q2	–	Sell	-261	Closed	-$28K	–	1086
2020 Q1	$28K	Buy	+261	New	+$30.1K	﹤0.01%	1343

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's ALNY Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, selling an estimated $70.6K and leaving 19,608 shares worth $5.9M. The position accounts for 0.06% of the portfolio, ranked #324.

Oppenheimer Asset Management first reported a position in ALNY in Q1 2020 and has held it in 6 quarters since. The position peaked at $6.57M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Oppenheimer Asset Management held 19,608 shares of Alnylam Pharmaceuticals worth $5.9M as of Q2 2026.
Oppenheimer Asset Management sold 234 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $70.6K.
Alnylam Pharmaceuticals made up 0.06% of Oppenheimer Asset Management's portfolio in Q2 2026, its #324 holding.
Oppenheimer Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 6 quarters since.
Oppenheimer Asset Management's Alnylam Pharmaceuticals position peaked at $6.57M in Q1 2026.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.